Imago BioSciences raises $80M to advance blood cancer therapy

Patients diagnosed with myeloproliferative neoplasm, a group of blood cancers in which the body overproduces red or white blood cells, don’t have great options. Treatment tends to be palliative, without changing the course of disease. Enter Imago BioSciences, which is working on a treatment that shuts down an enzyme important to cancer growth.